|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0035020,
umls-concept:C0178602,
umls-concept:C0205171,
umls-concept:C0205409,
umls-concept:C0332174,
umls-concept:C0392762,
umls-concept:C0457454,
umls-concept:C0935989,
umls-concept:C1444662,
umls-concept:C1513380,
umls-concept:C1521991,
umls-concept:C1540912
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-3-30
|
|
pubmed:abstractText |
Imatinib is the treatment of choice for FIP1L1-PDGFRalpha (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1161-3
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:18989670-Adult,
pubmed-meshheading:18989670-Dose-Response Relationship, Drug,
pubmed-meshheading:18989670-Drug Administration Schedule,
pubmed-meshheading:18989670-Drug Dosage Calculations,
pubmed-meshheading:18989670-Eosinophils,
pubmed-meshheading:18989670-Humans,
pubmed-meshheading:18989670-Hypereosinophilic Syndrome,
pubmed-meshheading:18989670-Leukocyte Count,
pubmed-meshheading:18989670-Male,
pubmed-meshheading:18989670-Oncogene Proteins, Fusion,
pubmed-meshheading:18989670-Patient Compliance,
pubmed-meshheading:18989670-Piperazines,
pubmed-meshheading:18989670-Pyrimidines,
pubmed-meshheading:18989670-Receptor, Platelet-Derived Growth Factor alpha,
pubmed-meshheading:18989670-Recurrence,
pubmed-meshheading:18989670-Remission Induction,
pubmed-meshheading:18989670-mRNA Cleavage and Polyadenylation Factors
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose.
|
|
pubmed:affiliation |
Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy. breccia@bce.uniroma1.it
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
